7 January 2016 - In an addendum, the IQWiG assessed study data submitted by BMS. In treatment-naive patients whose tumour is BRAF V600 mutation negative, IQWiG still sees a hint of an additional benefit in comparison with the appropriate comparator therapy for women, and an indication of an additional benefit for men. The extent of the additional benefit has increased from “minor” to “considerable” in women, and from “considerable” to “major” in men.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/nivolumab-in-melanoma-data-subsequently-submitted-improve-assessment-result.7129.html